Patents Represented by Attorney Tony W. Peng

Find this attorney in the Justia Lawyer Directory

  • Quinoline derivatives as PI3 kinase inhibitors
    Patent number: 8138347
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: March 20, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven David Knight, Stanley J. Schmidt
  • Substituted diketopiperazines and their use as oxytocin antagonists
    Patent number: 8071594
    Abstract: Compounds of formula (1) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2-methyl-1,3-oxazol-4-yl and R4 and R5 together with the notrogen atom to which they are attached represents morpholino, process for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: December 6, 2011
    Assignee: Glaxo Group Limited
    Inventor: John Liddle
  • Compounds
    Patent number: 7919492
    Abstract: Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: April 5, 2011
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Deirdre Mary Bernadette Hickey, John Liddle, Andrew McMurtrie Mason
  • Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors
    Patent number: 7897612
    Abstract: The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: March 1, 2011
    Assignee: Glaxosmithkline, LLC
    Inventors: Duke M. Fitch, Mariela Colón
  • Quinoxaline derivatives as PI3 kinase inhibitors
    Patent number: 7592342
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: September 22, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Yanhong Feng, Cynthia A. Parrish, Martha A Sarpong, Domingos J Silva
  • Piperazinediones as oxytocin receptor antagonists
    Patent number: 7550462
    Abstract: Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: June 23, 2009
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Deirdre Mary Bernadette Hickey, John Liddle, Andrew McMurtrie Mason
  • Substituted diketopiperazines as oxytocin antagonists
    Patent number: 7514437
    Abstract: A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Alan David Borthwick, Richard Jonathan Hatley, Deirdre Mary Bernadette Hickey, John Liddle, David George Hubert Livermore, Andrew McMurtrie Mason, Neil Derek Miller, Fabrizio Nerozzi, Steven Leslie Sollis, Anna Katrin Szardenings, Paul Graham Wyatt